Pharmaceutical, Drugs, Medicine, Biology, FDA.
50% of drugs fail at phase II clinical trials due to the lack of efficacy. In other words, the drug may be safe for humans, bind to the intended target, and have drug-like properties, but it does not significantly affect the disease being targeted. Key Challenges The following are some of the key